TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10335905
Drug: (S)-propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-propranolol 40 mg
Study: 10335905
Drug: (R)-propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-propranolol 40 mg
Study: 10335905
Drug: (R,S)-carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R,S)-carvedilol 25 mg
Study: 10335905
Drug: (R,S)-verapamil 120
Normalized name: verapamil hydrochloride 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R,S)-verapamil 120 mg
Study: 8724530
Drug: Amsacrine (AMSA)
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine (AMSA) 75 mg/m2/day x 4 plus continuous infusion high-dose cytarabine (CIHDAC) 1.5 g/m2/day x 4
Study: 8724530
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion high-dose cytarabine (CIHDAC) alone
Study: 16266472
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg per day)
Study: 6137327
Drug: Indapamide (used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (used alone or in combination)
Study: 31821355
Drug: 0.8% hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% hylan G-F 20 (control)
Study: 29916110
Drug: Intravenous carbetocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous carbetocin (100 mcg)
Study: 29916110
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (5 U)
Study: 24769332
Drug: AXT914 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXT914 45 mg
Study: 24769332
Drug: AXT914 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXT914 60 mg
Study: 24769332
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg Forteo/PTH(1-34) fragment)
Study: 21701082
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg daily, n=24)
Study: 21701082
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily, n=25)
Study: 19493295
Drug: Internet-based sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based sex therapy
Study: 17470830
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg of body weight)
Study: 7834003
Drug: 5-mL saline
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mL saline instillation
Study: 29915435
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention using wearable monitoring devices with IoT systems and monthly remote health guidance from a public health nurse.
Study: 12620952
Drug: Bronchodilator premedication
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator premedication (albuterol or ipratropium)
Study: 10695689
Drug: Low-dose antihypertensive
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antihypertensive therapy
Study: 8461472
Drug: 7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/d of a 85% omega-3 fatty acid fish oil concentrate
Study: 3026009
Drug: Sulbactam/ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam/ampicillin (1 g of sulbactam and 2 g of ampicillin three times a day for two weeks)
Study: 3026009
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g three times a day for two weeks)
Study: 20422202
Drug: Compound Imaging
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Imaging (CI)
Study: 20422202
Drug: Tissue Harmonic
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue Harmonic Compound Imaging (THICI)
Study: 19075138
Drug: Dapsone gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone gel, 5%
Study: 12460519
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormones (rhGH) 9 U/d
Study: 7700763
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg/day intravenously for 3 days, 0.25 mg/kg/day for 3 days, and 0.1 mg/kg/day for 1 day)
Study: 2199618
Drug: Chemotherapy (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (six IV cyclophosphamide, methotrexate, and fluorouracil courses followed by four IV epirubicin courses)
Study: 18028017
Drug: Tamoxifen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (5 years treatment)
Study: 8740786
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Tamoxifen
Study: 2199618
Drug: Chemotherapy (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (with or without tamoxifen)
Study: 21561896
Drug: GLP‐1 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 infusion
Study: 28374695
Drug: Cytoflavin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin 10 ml/day
Study: 28374695
Drug: Cytoflavin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin 20 ml/day
Study: 25888067
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of docetaxel + sunitinib
Study: 16042327
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GHTX)
Study: 16042327
Drug: Non-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment group (NonTX)
Study: 12476037
Drug: 800-mg oral
Normalized name: piracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-mg oral dose of telithromycin
Study: 12476037
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 400 mg telithromycin (young) or 480 mg telithromycin (elderly)
Study: 10731130
Drug: Tazarotene plus
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene plus mid- or high-potency topical corticosteroid
Study: 10731130
Drug: Tazarotene alternating
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene alternating with high-potency topical corticosteroid
Study: 6892711
Drug: Free milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free milk supplement (190 ml daily for six school terms)
Study: 31434111
Drug: Active homeopathic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active homeopathic medicine
Study: 9649059
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of LMW heparin (nadroparin) 12,500 ICU AXa at the beginning of dialysis
Study: 9649059
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of nadroparin 10,000 ICU AXa at the beginning of dialysis followed by a supplementary dose of nadroparin 2,500 ICU AXa at the beginning of the fifth hour of dialysis
Study: 7521582
Drug: Aprotinin in
Normalized name: aprotinin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin in standard doses
Study: 2672492
Drug: Diazemuls (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazemuls (10 mg)
Study: 2672492
Drug: Valium Mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valium Mixed Micelles (10 mg)
Study: 23891702
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) 0.5μg/(kg body weight) intravenously administered for 24h
Study: 21716251
Drug: Neyromidin (ipidacrinum)
Normalized name: ipidacrine
DrugBank: Ipidacrine (DB13668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neyromidin (ipidacrinum) used in intramuscular injections
Study: 21716251
Drug: Neyromidin (ipidacrinum)
Normalized name: ipidacrine
DrugBank: Ipidacrine (DB13668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neyromidin (ipidacrinum) introduced by local injection perineural therapy
Study: 19701041
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of re‐treatment
Study: 19701041
Drug: Overall improvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall improvement and treatment success rating
Study: 14647880
Drug: 17beta‐estradiol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 150 micro g
Study: 14647880
Drug: 17beta‐estradiol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 300 micro g
Study: 11721100
Drug: Tirofiban (body-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (body-weight adjusted intravenous) for a mean period of 46 hours
Study: 8334344
Drug: Verapamil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil plus Renal Disease Basic-prescription (RDBP)
Study: 3557792
Drug: Rifampicin in
Normalized name: Product containing rifampicin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin in combination with isoniazid
Study: 28470563
Drug: Qishen Yiqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Yiqi Dripping Pills (QSYQ)
Study: 28470563
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular medication only)
Study: 22626580
Drug: elocalcitol 75
Normalized name: Elocalcitol
DrugBank: Elocalcitol (DB06194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: elocalcitol 75 μg/d
Study: 22626580
Drug: elocalcitol 150
Normalized name: Elocalcitol
DrugBank: Elocalcitol (DB06194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: elocalcitol 150 μg/d
Study: 20838991
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for PMs
Study: 12932668
Drug: Concomitant alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant alternating chemotherapy and radiation at the coordinating centre
Study: 12932668
Drug: Concomitant alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant alternating chemotherapy and radiation at the affiliated centres
Study: 11916762
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (60 mg Fe/d, 4 d/wk for 16 wk)
Study: 25593015
Drug: Cetuximab 400mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly (Arm A)
Study: 25593015
Drug: Cetuximab 400mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab 400mg/m² IV on day 1 followed by 250mg/m² IV weekly plus sorafenib 400mg PO twice-a-day (Arm B)
Study: 23826087
Drug: Intralesional meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional meglumine antimoniate (i.l.MA)
Study: 23826087
Drug: Intralesional meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional meglumine antimoniate (i.l.MA) + non-silver dressing
Study: 23826087
Drug: Intralesional meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional meglumine antimoniate (i.l.MA) + silver dressing
Study: 15596636
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system, 30 mg/d
Study: 15596636
Drug: Hydrochlorothiazide-amiloride (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide-amiloride (25 mg/d of hydrochlorothiazide and 2.5 mg/d of amiloride hydrochloride)
Study: 15596636
Drug: Low creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low creatinine clearance (<60 mL/min)
Study: 11387278
Drug: Semen collection
Normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semen collection into 20 ml HEPES buffered Ham's F‐10 medium with 10% human serum albumin (group B)
Study: 3595971
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 1 mg of ONO-802 vaginal suppository every 3 hours (maximum of five suppositories)
Study: 3595971
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 1 mg of ONO-802 vaginal suppository (maximum of three suppositories)
Study: 30993934
Drug: Diabetic rabbits
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic rabbits with contrast agent (DCA)
Study: 30993934
Drug: Healthy rabbits
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy rabbits with contrast agent (NCA)
Study: 21598886
Drug: Closed reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed reduction (conservative treatment)
Study: 15570082
Drug: Bortezomib at
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib at 1.2 mg/m2/dose
Study: 15570082
Drug: Bortezomib at
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib at 1.6 mg/m2/dose
Study: 9549633
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg d-sotalol
Study: 9549633
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg d-sotalol
Study: 9549633
Drug: 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg d-sotalol
Study: 8368471
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefamandole administered preoperatively
Study: 8368471
Drug: Additional administration
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional administration of 1 g cefamandole before cardiopulmonary bypass
Study: 29180524
Drug: Omadacycline 300
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline 300 mg
Study: 29180524
Drug: Omadacycline 450
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline 450 mg
Study: 29180524
Drug: Omadacycline 600
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline 600 mg
Study: 20669674
Drug: TXLC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXLC + aspirin
Study: 17721640
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conventional knee and hip oriented rehabilitation programs
Study: 15730802
Drug: Rehabilitation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation group (routine treatment and early rehabilitation for 28 days, followed by community rehabilitation for 6 months or specialized reinforcement training for 2 months)
Study: 15730802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment and early rehabilitation for 28 days, followed by self-conducted rehabilitation training for 6 months)
Study: 11558795
Drug: Low CSF
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low CSF hypocretin levels (<100 pg/ml) in 32 of 38 patients (all HLA-positive)
Study: 9778000
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg propofol intravenously (group 2)
Study: 7873494
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of activated autologous peripheral blood lymphocytes (after cultivation with anti-CD3 antibody and IL-2)
Study: 29743098
Drug: HFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC at 30 l/min and 31 °C
Study: 29743098
Drug: HFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC at 60 l/min and 31 °C
Study: 29743098
Drug: HFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC at 60 l/min and 31 °C in patients with clinical FiO2 ≥ 45%
Study: 29743098
Drug: HFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC at 30 l/min and 37 °C
Study: 29743098
Drug: HFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC at 60 l/min and 37 °C
Study: 24587110
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment approaches (including reading fluency trainings, phonemic awareness instructions, reading comprehension trainings, auditory trainings, medical treatments, interventions with coloured overlays or lenses, sunflower therapy, motor exercises)
Study: 20950476
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg AMG 108
Study: 20950476
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg AMG 108
Study: 20950476
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg AMG 108
Study: 1827096
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg twice daily)
Study: 1827096
Drug: Roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (150 mg twice daily)
Study: 30979666
Drug: Psychosocial health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial health promotion intervention (manual‐based multi‐component health promotion program based on motivational interviewing and cognitive behavioral therapy)
Study: 27496630
Drug: Conservative transfusion
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative transfusion strategy (RBC transfusion for hemoglobin < 7.0 g/dL for biventricular repairs or < 9.0 g/dL for palliative procedures plus clinical indication)
Study: 27496630
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (RBC transfusion for hemoglobin < 9.5 g/dL for biventricular repairs or < 12 g/dL for palliative procedures regardless of clinical indication)
Study: 26561623
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (2.4 g/d) for 4 weeks
Study: 26561623
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (2.4 g/d) for 4 weeks + aspirin (300 mg/d) during the last 7 days
Study: 21216507
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of methylcobalamin and 5 mg of folic acid once daily for 24 months
Study: 8641826
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 24 months
Study: 17526862
Drug: G-CSF+ group
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF+ group (ATG, CyA, and G-CSF)
Study: 17526862
Drug: G-CSF- group
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF- group (ATG and CyA)
Study: 17526862
Drug: G-CSF+ group
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF+ group
Study: 17526862
Drug: G-CSF- group
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF- group
Study: 15446640
Drug: Ski lessons
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ski lessons only for two weeks, 2 to 4 hours daily
Study: 9536157
Drug: Antioxidant supplements
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplements (15 mg beta‐carotene, 75 mg vitamin E, and 650 mg vitamin C) once a day for three months
Study: 7625474
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day of haloperidol
Study: 7625474
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of haloperidol
Study: 7625474
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day of haloperidol
Study: 2186655
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 0.1 mg/kg
Study: 27473350
Drug: ACTH infusion
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH infusion
Study: 26372487
Drug: 4-week intensive
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week intensive fluconazole treatment for CrAg-positive patients
Study: 26372487
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (CrAg-negative patients)
Study: 14669315
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment for 12 months
Study: 14669315
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment-naïve)
Study: 1495849
Drug: Oral ribosomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ribosomal vaccine D53
Study: 1495849
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral ribosomal vaccine D53
Study: 6716521
Drug: 10-gauge Angiocath
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-gauge Angiocath and 8 Fr pulmonary artery introducer catheter with large-bore intravenous tubing (5.0 mm I.D.)
Study: 6716521
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous tubing (3.2 mm I.D.)
Study: 12133187
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for sepsis